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The most common cause of hypercalcemia in hospitalized patients is malignancy. Primary hyperparathyroidism most commonly
causes hypercalcemia in the outpatient setting.These two account for over 90% of all cases of hypercalcemia. Hypercalcemia can be
divided into PTH-mediated and PTH-independent variants. Primary hyperparathyroidism, familial hypocalciuric hypercalcemia,
familial hyperparathyroidism, and secondary hyperparathyroidism are PTHmediated. The most common PTH-independent type
of hypercalcemia is malignancy related. Several mechanisms lead to hypercalcemia in malignancy-direct osteolysis by metastatic
disease or, more commonly, production of humoral factors by the primary tumor also known as humoral hypercalcemia of
malignancy that accounts for about 80% of malignancy-related hypercalcemia.Themajority of HHM is caused by tumor-produced
parathyroid hormone-related protein and less frequently production of 1,25-dihydroxyvitamin D or parathyroid hormone by the
tumor. We report the rare case of a patient with hypercalcemia and diagnosed primary hyperparathyroidism. The patient had
persistent hypercalcemia after surgical removal of parathyroid adenoma with recorded significant decrease in PTH level. After
continued investigation it was found that the patient also had elevated 1,25-dihydroxyvitamin D and further studies confirmed a
large spleen mass that was later confirmed to be a lymphoma. This is a rare example of two concomitant causes of hypercalcemia
requiring therapy.
1. Introduction
Hypercalcemia is defined as total serum calcium above
10.5mg/dL (>2.6mmol/L). In a pregnant patient the upper
limit of normal is considered to be 9.5mg/dL [1]. The most
common cause of hypercalcemia in hospitalized patients is
malignancy. Primary hyperparathyroidism most commonly
causes hypercalcemia in the outpatient setting [2]. These two
account for over 90% of all cases of hypercalcemia.
Hypercalcemia can be divided into PTH-mediated and
PTH-independent variants. Primary hyperparathyroidism
(PHPT), familial hypocalciuric hypercalcemia, familial
hyperparathyroidism, and secondary hyperparathyroidism
are PTHmediated. In these patients initial evaluation reveals
increased or inappropriately normal PTH (not suppressed in
the setting of hypercalcemia) which narrows the differential
diagnosis. The most common PTH-independent type of
hypercalcemia is malignancy related. Several mechanisms
lead to hypercalcemia in malignancy-direct osteolysis by
metastatic disease or, more commonly, production of
humoral factors by the primary tumor also known as
humoral hypercalcemia of malignancy (HHM) that accounts
for about 80% of malignancy-related hypercalcemia. The
majority of HHM is caused by tumor-produced parathyroid
hormone-related protein (PTHrP) and, less frequently,
production of 1,25-dihydroxyvitamin D (1,25D) or para-
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Table 1: Pertinent labs before and after parathyroidectomy and resection of the spleen.
Lab On firstpresentation
After
parathyroidectomy
Postop. day 1
After
parathyroidectomy
Postop. day 10
After
splenectomy
∼One year after
splenectomy
Total calcium (mg/dL) 16.3 11.1 12.9 10.6 8.9
PTH (pg/mL) 58 5 4 5 78
Creatinine (mg/dL) 4.9 0.9 1.8 1.3 1.29
25D (pg/mL) 22 19 19 18.5 37
1.25D (pg/mL) >220 133.6 62
PTHrP (pmol/L) <2
Table 2: The literature review of reported cases of hypercalcemia and malignancy.
Study Basic study features Cause of hypercalcemia
Strodel et al. [9] 18 patients with malignancy and hypercalcemia All patients had PHPT as the only cause ofhypercalcemia.
Hutchesson et al. [10] 47 patients with malignancy and hypercalcemia
3 of 47 patients had PHPT as the cause of
hypercalcemia. No cases of 2 causes of elevated
calcium levels.
Owen et al. [11] 2 cases of primary cutaneous lymphomas andhypercalcemia
Both cases were found to have PHPT as the only
cause of hypercalcemia
Albe`s et al. [12] A case of T-cell lymphoma and hypercalcemia Hypercalcemia caused by PHPT only
Aguilar-Bernier et al.
[13] Lymphomatoid papulosis Hypercalcemia caused by PHPT only
Gallacher et al. [14]
Hypercalcemia did not resolve after removal of
parathyroid adenoma which prompted further
workup and the patient was found to have
malignancy in the manubrium sterni
One case with two coexisting mechanisms of
hypercalcemia—PHPT and PTHrP mediated
Luceri and Haenel
[15]
Hypercalcemia did not resolve after removal of
parathyroid adenoma which prompted further
workup and the patient was found to have diffuse
large B-cell lymphoma
One case with two coexisting mechanisms of
hypercalcemia—PHPT and 1,25-dihydroxyvitamin
D mediated
Figure 1: Abdominal CT showing splenic mass.
thyroid hormone by the tumor [3]. Tumors secreting PTHrP
cause increased bone resorption and distal renal tubular
calcium reabsorption. Tumors that cause elevation in 1,25D
cause hypercalcemia as a result of a combination of increased
bone resorption and intestinal calcium absorption.
Primary hyperparathyroidism with an adenoma or
hyperplasia producing hypercalcemia is a relatively com-
mon endocrine problem that is treated surgically. If the
hypercalcemia persists after resection of an adenoma, then
the differential diagnosis would depend on whether the
hypercalcemia is associated with a relatively high or a low
PTH. With a high PTH the surgeon needs to seek another
adenoma or parathyroid hyperplasia. With a low PTH,
hypercalcemia must depend on other causes that have to be
sought.
We report the rare case of a patient with two concomitant
causes of hypercalcemia requiring therapy.
2. Case
A previously healthy 67-year-old man was taken to the
emergency room for polyuria, unsteady gait, dizziness, and
confusion. The patient was found to have a calcium level
of 16.3mg/dL (reference range 8.6–10.2) and acute renal
failure with a Cr of 4.9mg/dL. The PTH level was elevated
at 58 pg/mL (11–51 pg/mL). He was treated with IV fluids,
calcitonin, and one dose of pamidronate. His serum calcium
and creatinine improved. An ultrasound of the neck was
consistent with a right inferior parathyroid mass that on
surgical removal was confirmed by histopathology to be a
parathyroid adenoma. Intraoperatively his PTH fell from51 to
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Figure 2: (a) H&E, 40x: sections of the spleen show a proliferation of highly atypical large lymphoid cells resulting in extensive effacement of
the splenic architecture.The cells show irregular nuclei with open vesicular chromatin, prominent nucleoli, andmoderate to scant cytoplasm.
Abundant mitotic figures are seen. (b) Immunohistochemistry, CD20, 40x: the neoplastic lymphoid cells exhibit diffuse and strong staining
for CD20. (c) Immunohistochemistry, 1-alpha-hydroxylase, 40x: neoplastic lymphoid cells exhibit moderate, irregular immunoreactivity for
1-alpha-hydroxylase in a cytoplasmic distribution.
10 pg/mL.The serum calcium at 11.1mg/dL did not normalize
following the surgery.
His creatinine became normal and the PTH remained low
at 5 pg/mL. Workup for persistent hypercalcemia revealed
a normal PTHrP and a high 1,25-dihydroxyvitamin D of
>200 pg/mL (reference range: 15–75) indicating the addi-
tional mechanism of hypercalcemia (Table 1).
His previous workup was negative for sarcoidosis and
multiple myeloma and he never took any vitamin D or
calcium supplements. An abdominal CT scan showed a
splenic mass (Figure 1).
Following the resection of this mass the calcium level
normalized. The mass was found to be a diffuse large B-
cell lymphoma. Immunohistochemistry showed that neo-
plastic lymphoid cells exhibit strong staining for CD20. Most
importantly, from the hypercalcemia perspective, it shows
immunoreactivity for 1-alpha-hydroxylase in a cytoplasmic
distribution (Figures 2(a), 2(b), and 2(c)).
3. Discussion
Hypercalcemia is a relatively frequent complication of lym-
phoma [4]. Increased circulating levels of 1,25D have been
described in patients withHodgkin’s and non-Hodgkin’s lym-
phomas [5, 6]. Calcidiol (25-hydroxyvitamin D) is metabol-
ically activated in the proximal convoluted tubule cells of
the kidney to produce calcitriol (1,25D) by 1-alpha hydrox-
ylase. This reaction is stimulated by PTH, calcitonin, and
hypophosphatemia and inhibited by calcium, 1,25D, and
hyperphosphatemia [7]. 1-Alpha-hydroxylase belongs to the
cytochrome p450 superfamily of enzymes and is encoded by
the CYP27B1 gene.
Hewison and colleagues used immunohistochemistry to
demonstrate the presence of 1𝛼-hydroxylase in macrophages
associated with lymphomas. They suggested that the tumor
secreted factors that stimulated 1𝛼-hydroxylase expression by
macrophages [8].
Some studies have claimed that 15% of patients with
hypercalcemia and malignancy have coexisting hyperpara-
thyroidism (Table 2). A report by Strodel et al. in 1988
shows a group of 18 patients with malignant tumors and
hypercalcemia caused by PHPT. In all cases, serum levels
of calcium returned to normal after surgical removal of
a parathyroid adenoma or hyperplasia indicating that the
hypercalcemia was caused by only one mechanism [9].
Hutchesson et al. report 47 patients with hypercalcemia
and malignancy; however, in three patients it was found
that hypercalcemia was caused by PHPT and hypercalcemia
resolved after surgical removal of a parathyroid adenoma
[10]. Owen et al. report 2 cases of parathyroid adenoma in
patients with primary cutaneous lymphomas [11]. In both
cases serum calcium levels returned to normal after removal
of the parathyroid adenoma. Neither PTHrP nor 1,25D levels
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were assessed. Two additional isolated cases of parathyroid
adenoma causing hypercalcemia in patients with T-cell lym-
phoma [12] and lymphomatoid papulosis [13] were reported
subsequently.
In all but two reports the hypercalcemia was caused
by only one mechanism. A patient of Gallacher et al. was
found to have persistent hypercalcemia after a parathyroid
adenoma was removed and PTH levels fell, leading to further
investigation that revealed elevated PTHrP and a carcinoma
in the manubrium [14]. The humoral mechanism via PTHrP,
however, was different than our patient’s who had 1,25D
elevation. The only report to our knowledge of coexisting
PHPT and diffuse large B-cell lymphoma causing 1,25D
elevation and multifactorial hypercalcemia was published in
2013 by Luceri and Haenel IV [15].
Two distinct causes of hypercalcemia may coexist by
chance. Some authors have also suggested that hyperparathy-
roidism may be associated with the slight increase in the
incidence of malignancy [16]. At this time we do not know
whether there is any relation between lymphoma and PHPT.
Persistence of hypercalcemia after removal of the causal
lesion should prompt a thorough workup for another source
based on whether the offending agent is PTH, PTHrP, or
Vitamin D.
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